Healio Capecitabine demonstrated encouraging efficacy and toxicity outcomes compared with gemcitabine in a cohort of patients with locally advanced pancreatic cancer, according to phase 2 results of the SCALOP trial. Researchers conducted the open-label, ...
Seeking Alpha Late Wednesday, the company said that positive clinical data from a Phase 1b trial of PEGPH20 in combination with gemcitabine to treat patients with stage IV metastatic pancreatic cancer will be presented at the 2013 American Society of Clinical ...
MarketWatch (blog) The company put out a release late Wednesday saying it would discuss full results from a Phase 1 study on the drug, now dubbed PEGPH20, used in combin...
OncLive Yang said the results of the LUX-Lung 6 trial, which was similar in design to LUX-Lung 3, but used gemcitabine plus cisplatin as the control, will likely be presented at the 2013 ASCO Annual Meeting. Additionally, LUX-Lung 7 is continuing to enroll ... and more »
Healio Maintenance therapy with paclitaxel and gemcitabine improved PFS and OS in women with metastatic breast cancer who initially exhibited disease control after first-line treatment with six cycles of the same combination, according to results of a phase 3 ...
GSPInsider This breaks down hyaluronic acid (HA) temporarily. This is a naturally-occurring substance that is a component of the extra-cellular matrix in tissues right through the body, such as cartilage and skin. Boulder Brands Inc (NASDAQ:BDBD): In Friday's ...
Healio Capecitabine demonstrated encouraging efficacy and toxicity outcomes compared with gemcitabine in a cohort of patients with locally advanced pancreatic cancer, according to phase 2 results of the SCALOP trial. Researchers conducted the open-label, ...
Openglobe The company, on May 15, announced that clinical data from a Phase 1b trial of PEGPH20 (PEGylated Recombinant Human Hyaluronidase), an investigational new biologic, in combination with gemcitabine for treatment of patients with stage IV metastatic ...
Wall Street Journal (press release) Abstract Conclusions: In this patient population with extensive disease burdens and limited treatment options, bavituximab plus gemcitabine was well tolerated and demonstrated moderate activity in tumor response and survival. About Bavituximab: A ... and more »
